

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, Sequence Search, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HABERHAUSEN ET AL: "Comparative study of different standardization concepts in quantitative competitive reverse transcription PCR-assays"</p> <p>JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 36, no. 3, March 1998 (1998-03), pages 628-633, XP002132721</p> <p>ISSN: 0095-1137</p> <p>abstract</p> <p>page 630, column 2, paragraph 2</p> <p>page 631, column 1, paragraph 2 - page 633, column 1, paragraph 1; figures 3,4</p> <p style="text-align: center;">-/-</p>	1-3,5-8, 11-32

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

15 July 2004

Date of mailing of the international search report

05/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Bradbrook, D

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 91/02817 A (CETUS CORP) 7 March 1991 (1991-03-07) page 11, line 23 - page 14, line 18; figure 1; examples 1-4 page 20, lines 6-24	1-3,5-8, 11-32
X	ZAMORANO P L ET AL: "QUANTITATIVE RT-PCR FOR NEUROENDOCRINE STUDIES A MINIREVIEW" NEUROENDOCRINOLOGY, S.KARGER, BASEL, CH, vol. 63, 1996, pages 397-407, XP002941018 ISSN: 0028-3835 page 400, column 1, paragraph 2 - page 406, column 1, paragraph 1; figures 1,2	1-3,5-8, 11-32
X	JENSEN LISELOTTE E ET AL: "Competitive reverse transcription polymerase chain reaction for quantifying pre-mRNA and mRNA of major acute phase proteins." JOURNAL OF IMMUNOLOGICAL METHODS, vol. 215, no. 1-2, 1 June 1998 (1998-06-01), pages 45-58, XP004146492 ISSN: 0022-1759 abstract; figures 2,5 page 54, column 2, paragraph 1 - page 55, column 2, paragraph 1	1-3,5-8, 11-32
X	SHEFLIN LOWELL G ET AL: "Thyroxine increases the levels of epidermal growth factor messenger ribonucleic acid (EGF mRNA) in the thyroid in vivo, as revealed by quantitative reverse transcription polymerase chain reaction with an internal control EGF mRNA." ENDOCRINOLOGY, vol. 132, no. 6, 1993, pages 2319-2324, XP002253790 ISSN: 0013-7227 abstract; figure 1 page 2319, column 1, paragraph 1 - column 2, paragraph 1	1-3,5-8, 11-32
X	CLELAND A ET AL: "USE OF BOVINE VIRAL DIARRHOEA VIRUS AS AN INTERNAL CONTROL FOR AMPLIFICATION OF HEPATITIS C VIRUS" VOX SANGUINIS, S. KARGER AG, BASEL, CH, vol. 76, no. 3, 1999, pages 170-174, XP000956256 ISSN: 0042-9007 page 171, column 2, paragraphs 2,3 page 172, column 2, paragraphs 1,2	1-32
	----- -/--	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 277 560 B1 (LU WEI ET AL) 21 August 2001 (2001-08-21) column 4, lines 47-55; claim 5; examples 8-10	1-32
X	GIBSON U E M ET AL: "A NOVEL METHOD FOR REAL TIME QUANTITATIVE RT-PCR" GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 6, no. 10, 1 October 1996 (1996-10-01), pages 995-1001, XP000642796 ISSN: 1088-9051 cited in the application the whole document	1-3,5-8, 11-32
X	WO 01/16367 A (PERKIN ELMER CORP) 8 March 2001 (2001-03-08) page 13, line 1 - page 17, line 6 page 24, lines 21,22; example 2	1-32
X	EP 1 236 804 A (HOFFMANN LA ROCHE ; ROCHE DIAGNOSTICS GMBH (DE)) 4 September 2002 (2002-09-04) page 3, lines 11-42 page 4, lines 14-47	1-32
X	US 6 312 929 B1 (MCMILLAN WILLIAM A) 6 November 2001 (2001-11-06) the whole document	1-32
A	SIEBERT P D ET AL: "COMPETITIVE PCR" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 359, 8 October 1992 (1992-10-08), pages 557-558, XP002071876 ISSN: 0028-0836 the whole document	1-32
A	REISCHL U ET AL: "QUANTITATIVE PCR A SURVEY OF THE PRESENT TECHNOLOGY" MOLECULAR BIOTECHNOLOGY, TOTOWA, NJ, US, vol. 3, 1995, pages 55-71, XP000600241 ISSN: 1073-6085 the whole document	1-32

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9102817	A	07-03-1991	US	5219727 A	15-06-1993
			AT	178656 T	15-04-1999
			AU	653920 B2	20-10-1994
			AU	6352390 A	03-04-1991
			CA	2064906 A1	22-02-1991
			DE	69033044 D1	12-05-1999
			DE	69033044 T2	25-11-1999
			DK	497784 T3	18-10-1999
			EP	0497784 A1	12-08-1992
			ES	2132069 T3	16-08-1999
			JP	3331178 B2	07-10-2002
			JP	11123095 A	11-05-1999
			JP	2878453 B2	05-04-1999
			JP	5504886 T	29-07-1993
			US	5476774 A	19-12-1995
			WO	9102817 A1	07-03-1991
US 6277560	B1	21-08-2001	FR	2740781 A1	09-05-1997
			AU	7500496 A	29-05-1997
			BR	9611334 A	06-04-1999
			CA	2236842 A1	15-05-1997
			CZ	9801205 A3	12-08-1998
			EA	613 B1	29-12-1999
			EP	0862654 A1	09-09-1998
			WO	9717465 A1	15-05-1997
			FR	2740782 A1	09-05-1997
			JP	2000500007 T	11-01-2000
			NO	982039 A	05-05-1998
WO 0116367	A	08-03-2001	US	5952202 A	14-09-1999
			AU	3372799 A	26-03-2001
			EP	1104487 A1	06-06-2001
			WO	0116367 A1	08-03-2001
EP 1236804	A	04-09-2002	EP	1236804 A1	04-09-2002
			CA	2371672 A1	02-09-2002
			CN	1386865 A	25-12-2002
			EP	1236805 A1	04-09-2002
			JP	2002335981 A	26-11-2002
			US	2003054372 A1	20-03-2003
			US	2003165982 A1	04-09-2003
US 6312929	B1	06-11-2001	EP	1352091 A2	15-10-2003
			WO	02052030 A2	04-07-2002
			US	2002119464 A1	29-08-2002